Cargando…
Regulatory oversight on the use of experimental therapies during a pandemic: The case of early access to convalescent plasma therapy in three LMICs
Clinicians, especially in low- and middle-income countries (LMICs), contend with limited economic and healthcare resources in deciding appropriate and feasible care for their patients. Some of the LMICs affected by COVID-19 implemented convalescent plasma therapy without sufficient regulatory guidan...
Autores principales: | Bernabe, Rosemarie, Torres, Cristina, Wangge, Grace, Jimenez, Edlyn, Karbwang, Juntra |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Author(s). Published by Elsevier Ltd.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8664719/ https://www.ncbi.nlm.nih.gov/pubmed/34906688 http://dx.doi.org/10.1016/j.drudis.2021.12.002 |
Ejemplares similares
-
Regulatory Oversight and Safety of Probiotic Use
por: Venugopalan, Veena, et al.
Publicado: (2010) -
Are dental schools doing enough to prepare dental hygiene & therapy students for direct access?
por: D. D. Quach, Joshua, et al.
Publicado: (2020) -
The resurgence of convalescent plasma therapy
por: The Lancet Haematology
Publicado: (2020) -
Pharmacokinetics and pharmacodynamics of fosmidomycin monotherapy and combination therapy with clindamycin in the treatment of multidrug resistant falciparum malaria
por: Na-Bangchang, Kesara, et al.
Publicado: (2007) -
Is it time to reform oversight of clinical gene therapy in the EU?
por: Kenter, Marcel J.H.
Publicado: (2018)